Ivabradina Tarbis Farma (Ivabradine)

Ivabradine selectively blocks the funny (If) current in the sino‑atrial node by binding to HCN channels. This inhibition slows the spontaneous depolarisation of pacemaker cells, leading to a lower heart rate while preserving myocardial contractility and blood pressure.

The dose of ivabradine is individualized by the prescribing clinician based on the patient’s heart‑rate, clinical condition, and concomitant therapies. The prescriber determines the appropriate strength, frequency, and any necessary titration, following local labeling and guideline recommendations.

Safety data for ivabradine during pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Clinicians should discuss individual risk factors with the patient and consider alternative therapies when possible.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

The primary alternative for heart‑rate reduction in heart failure and angina is the beta‑blocker class. Unlike beta‑blockers, ivabradine lowers heart rate without affecting contractility or blood pressure, making it useful when beta‑blockers are contraindicated, not tolerated, or insufficient to achieve target heart rates.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use. Do not store in a refrigerator or freezer.

Ivabradina Tarbis Farma is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. Dosing times are typically spaced evenly (e.g., twice daily) as directed by the prescriber, and the medication should be taken with or without food according to label instructions.

The most serious adverse events include symptomatic bradycardia, atrial fibrillation, and severe allergic reactions such as rash, angioedema, or anaphylaxis. Patients should be instructed to report any new or worsening chest discomfort, fainting, palpitations, or visual disturbances promptly.

Ivabradine is contraindicated in patients with severe hepatic impairment, acute decompensated heart failure, sick sinus syndrome, or a resting heart rate below 50 bpm. It should also be avoided in individuals with known hypersensitivity to ivabradine or any of the tablet’s excipients.